mug191 Antibody

Introduction to the H1-84 Monoclonal Antibody (mAb) Targeting the HA191/199 Region

The H1-84 monoclonal antibody (mAb) is a murine-derived immunoglobulin G (IgG) that specifically recognizes the HA191/199 region of the H1N1 influenza virus hemagglutinin (HA) protein. This epitope is a nine-amino-acid linear sequence (191-LVLWGIHHP-199) located in the HA head domain, a critical structural component of the virus responsible for binding host cell receptors . The antibody was developed to investigate its potential as a therapeutic or diagnostic tool, particularly in addressing vaccine-induced immune reactions and neural complications .

2.1. Epitope Mapping and Cross-Reactivity

The HA191/199 region is critical for maintaining the HA head structure, as its removal requires site-directed mutagenesis to avoid destabilizing the protein . H1-84 mAb exhibits cross-reactivity with human neuronal proteins, including heterophile antigens, which may contribute to vaccine-associated neurotoxicity .

2.2. Neural Cell Damage

In vitro studies using flow cytometry and immunofluorescence revealed that H1-84 mAb binds to neural cells and induces damage, potentially via antibody-dependent cellular cytotoxicity (ADCC) or complement activation . This mechanism aligns with observed adverse reactions in multiple sclerosis patients who produce anti-hnRNP antibodies .

Implications for Vaccine Development

The H1-84 mAb highlights challenges in influenza vaccine design, particularly the risk of inducing autoantibodies targeting neural antigens. Researchers propose modifying the HA191/199 region via point mutations to mitigate cross-reactivity while preserving vaccine efficacy . This approach could reduce neurotoxic side effects while maintaining immunogenicity against the virus.

3.1. Proposed Modifications

• Mutagenesis: Introduce substitutions in the HA191/199 sequence to disrupt antibody binding without altering viral infectivity .

• Structural Analysis: Use molecular modeling tools (e.g., PyMOL) to predict how mutations affect epitope accessibility .